Anti-AXIN2/ AXIL/ ODCRCS monoclonal antibody
Anti-AXIN2/ AXIL/ ODCRCS antibody for FACS & in-vivo assay
Go to AXIN2/AXIN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP2013-Ab-1/ GM-Tg-hg-MP2013-Ab-2 | Anti-Human AXIN2 monoclonal antibody | Human |
GM-Tg-rg-MP2013-Ab-1/ GM-Tg-rg-MP2013-Ab-2 | Anti-Rat AXIN2 monoclonal antibody | Rat |
GM-Tg-mg-MP2013-Ab-1/ GM-Tg-mg-MP2013-Ab-2 | Anti-Mouse AXIN2 monoclonal antibody | Mouse |
GM-Tg-cynog-MP2013-Ab-1/ GM-Tg-cynog-MP2013-Ab-2 | Anti-Cynomolgus/ Rhesus macaque AXIN2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP2013-Ab-1/ GM-Tg-felg-MP2013-Ab-2 | Anti-Feline AXIN2 monoclonal antibody | Feline |
GM-Tg-cang-MP2013-Ab-1/ GM-Tg-cang-MP2013-Ab-2 | Anti-Canine AXIN2 monoclonal antibody | Canine |
GM-Tg-bovg-MP2013-Ab-1/ GM-Tg-bovg-MP2013-Ab-2 | Anti-Bovine AXIN2 monoclonal antibody | Bovine |
GM-Tg-equg-MP2013-Ab-1/ GM-Tg-equg-MP2013-Ab-2 | Anti-Equine AXIN2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP2013-Ab-1/ GM-Tg-hg-MP2013-Ab-2; GM-Tg-rg-MP2013-Ab-1/ GM-Tg-rg-MP2013-Ab-2; GM-Tg-mg-MP2013-Ab-1/ GM-Tg-mg-MP2013-Ab-2; GM-Tg-cynog-MP2013-Ab-1/ GM-Tg-cynog-MP2013-Ab-2; GM-Tg-felg-MP2013-Ab-1/ GM-Tg-felg-MP2013-Ab-2; GM-Tg-cang-MP2013-Ab-1/ GM-Tg-cang-MP2013-Ab-2; GM-Tg-bovg-MP2013-Ab-1/ GM-Tg-bovg-MP2013-Ab-2; GM-Tg-equg-MP2013-Ab-1/ GM-Tg-equg-MP2013-Ab-2 |
Products Name | Anti-AXIN2 monoclonal antibody |
Format | mab |
Target Name | AXIN2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-AXIN2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species AXIN2/ AXIL/ ODCRCS VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP2013 |
Target Name | AXIN2 |
Gene ID | 8313,12006,29134,718566,490903,101093061,511619,100630049 |
Gene Symbol and Synonyms | Axi1,AXIL,axin-2,AXIN2,Conductin,ODCRCS |
Uniprot Accession | Q9Y2T1,O70240 |
Uniprot Entry Name | AXIN2_HUMAN,AXIN2_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | Cancer |
Gene Ensembl | ENSG00000168646 |
Target Classification | Tumor-associated antigen (TAA) |
The target: AXIN2, gene name: AXIN2, also named as AXIL, ODCRCS. The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.